$ABCL Sarah Noonberg just now:
“37% of ABCL635 patients had complete, or 100% resolution of moderate or severe events, compared to 2.2% of placebo patients. To our knowledge, comparable levels of complete resolution of moderate to severe events has not been reported for any
